<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860117</url>
  </required_header>
  <id_info>
    <org_study_id>1551628</org_study_id>
    <nct_id>NCT02860117</nct_id>
  </id_info>
  <brief_title>Ketamine Continuous Infusion on Opioid Consumption and Pain Management in Severe Burned Patients</brief_title>
  <acronym>ccimb</acronym>
  <official_title>The Effectiveness of Ketamine Continuous Infusion on Opioid Consumption and Pain Management in Severe Burned Patients, a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ketamine in continuous infusion in&#xD;
      the control of pain intensity, the impact on the consumption of opioids and observe the side&#xD;
      effect profile in patients suffering from great extent of burns.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in pharmacology and in analgesic techniques, pain in burned patients is&#xD;
      unwieldy yet, this occurs in such cases due to the complexity and intensity and the need for&#xD;
      multidisciplinary medical team. The burn pain is classified as nociceptive, but can also&#xD;
      present a neuropathic component. Overall this is a pain at rest and during movement, being&#xD;
      aggravated by procedures like changing dressings. In the weeks after the burn there is&#xD;
      intense pain due to injury and the management of the framework, which often involves dressing&#xD;
      changes and other procedures such as surgery in donor area skin.&#xD;
&#xD;
      The use of opioids in high doses can lead to unwanted side effects.To reduce the adverse&#xD;
      effects resulting from the use of opioids in high doses, we purpose the use of intravenous&#xD;
      continuous infusion of ketamine. In controlling the pain of major burned patient there is&#xD;
      evidence only of the use of ketamine in the form of intermittent boluses, especially during&#xD;
      dressing changes or in the perioperative period. The use of ketamine in continuous infusion&#xD;
      lacks evidence in this group of patients The purpose of this study is to evaluate the&#xD;
      efficacy of ketamine in continuous infusion in the control of pain intensity, the impact on&#xD;
      the consumption of opioids and observe the side effect profile in patients suffering from&#xD;
      great extent of burns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    change in hospital policy&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Rescue analgesic demand will be evaluated through patient controlled analgesia device up to 10 days of intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects questionnaire</measure>
    <time_frame>up to 10 days</time_frame>
    <description>the research team using a side effects questionnaire based on the major ketamine and opioid side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain, Burning</condition>
  <arm_group>
    <arm_group_label>Ketatamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketamine continuous infusion 0,2mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ketamine continuous infusion</intervention_name>
    <description>Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)</description>
    <arm_group_label>Ketatamine</arm_group_label>
    <other_name>Ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo continuous infusion (0,2 ml/kg/h)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl 0,9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria will be considered:&#xD;
&#xD;
          1. patients admitted to the burn unit of the Clinical Hospital with burnt body area of&#xD;
             25% or more;&#xD;
&#xD;
          2. aged between 18 and 60 years;&#xD;
&#xD;
          3. with surgical risk classification according to the &quot;American Society of&#xD;
             Anesthesiologists' (ASA) I and II;&#xD;
&#xD;
          4. has no known allergy or any other contraindications of the drugs that are used in the&#xD;
             treatment protocol;&#xD;
&#xD;
          5. hemodynamically stable, considering systolic blood pressure greater than 90 mmHg;&#xD;
&#xD;
          6. with preserved consciousness level, measured by the Glasgow coma scale, with a score&#xD;
             equal to 15;&#xD;
&#xD;
          7. with the possibility of drug administration orally or by naso-gastric tube&#xD;
&#xD;
        Exclusion criteria will be considered:&#xD;
&#xD;
          1. patients younger than 18 or older than 60 years;&#xD;
&#xD;
          2. with surgical risk classification according to the &quot;American Society of&#xD;
             Anesthesiologists' (ASA) III or higher;&#xD;
&#xD;
          3. with known allergy or any contraindications of the drugs that are used in the&#xD;
             treatment protocol;&#xD;
&#xD;
          4. patients with q chronic pain or chronic analgesic users prior to burning in treatment;&#xD;
&#xD;
          5. hemodynamically unstable, considering systolic blood pressure below 90 mm Hg;&#xD;
&#xD;
          6. with changing level of consciousness;&#xD;
&#xD;
          7. without the possibility of administering drugs orally or by nasogastric tube.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Palmeira, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Cl√≠nicas da FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Felipe Chiodini Machado</investigator_full_name>
    <investigator_title>Anesthesiologist, Member of USaoPauloGH Pain Management staff, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>ketamine</keyword>
  <keyword>continuous infusion</keyword>
  <keyword>severe burned patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

